Autoimmune inner ear disease patient–associated 28-kDa proinflammatory IL-1β fragment results from caspase-7–mediated cleavage in vitro
Shresh Pathak, Andrea Vambutas
Shresh Pathak, Andrea Vambutas
Published February 13, 2020
Citation Information: JCI Insight. 2020;5(3):e130845. https://doi.org/10.1172/jci.insight.130845.
View: Text | PDF
Research Article Otology

Autoimmune inner ear disease patient–associated 28-kDa proinflammatory IL-1β fragment results from caspase-7–mediated cleavage in vitro

Abstract

Interleukin-1β (IL-1β) is a key proinflammatory cytokine involved in the progression of many autoinflammatory and autoimmune diseases, including autoimmune inner ear disease (AIED). IL-1β inhibition has been shown to result in clinical hearing improvement in a small cohort of corticosteroid-resistant patients with AIED. Canonical processing of pro–IL-1β by caspase-1 generates an active 17-kDa fragment, capable of instigating a proinflammatory microenvironment. However, in response to LPS, PBMCs from patients with AIED uniquely express a 28-kDa IL-1β fragment, as compared with PBMCs from control subjects. We synthesized and compared the biologic activity of the 28-kDa fragment to the 17-kDa IL-1β product and the pro–IL-1 31-kDa protein. The 28-kDa IL-1β fragment induces IL-6, TNF-α, and CCL3 in PBMCs. Uniquely, only caspase-7 treatment showed a dose- and time-dependent increase in 28-kDa band generation. Mass spectrometry confirmed the putative caspase-7 cleavage site of pro–IL-1β, which was used to generate the 28-kDa fragment used for PBMC stimulation studies. Collectively, these results provide insight into the function of a poorly understood, processed 28-kDa form of IL-1β in patients with AIED that is uniquely generated by caspase-7 and is capable of activating further downstream proinflammatory cytokines. Further investigation may provide novel pharmacologic targets for the treatment of this rare disease.

Authors

Shresh Pathak, Andrea Vambutas

×

Figure 4

The 28-kDa fragment of IL-1β induces release of CCL3, TNF-α, and MMP-9.

Options: View larger image (or click on image) Download as PowerPoint
The 28-kDa fragment of IL-1β induces release of CCL3, TNF-α, and MMP-9. ...
PBMCs of patients with AIED and controls (n is shown for each panel) were treated with 1 μg/mL LPS (positive control); rIL-1β; or 17-kDa, 28-kDa, and 31-kDa (negative control) fragments of IL-1β or left untreated (16 hours). Cytokines were measured by ELISA from the culture supernatants. Data represent the mean ± SEM in all panels. (A) The concentration of CCL3 was measured by ELISA from the culture supernatants. A trend was observed in control PBMCs in response to the 28-kDa fragment as compared with the 17-kDa fragment (P = 0.027). (B) The TNF-α concentration was determined using a TNF-α ELISA kit. A statistically significant difference was observed in control PBMCs in response to the 28-kDa fragment as compared with the 17-kDa fragment (P = 0.008). (C) IL-6 concentrations in culture supernatants were determined by ELISA. (D) MMP-9 levels were detected by ELISA in the culture supernatant. A trend was observed in control PBMCs in response to the 28-kDa fragment as compared with the 17-kDa fragment (P = 0.027). (E) TIMP-1 supernatant concentrations were similarly measured by ELISA. (F) To determine whether the 28-kDa fragment of IL-1β had antiinflammatory properties, PBMCs of AIED and control subjects were assayed for IL-4 release by ELISA. For A–F, the Wilcoxon signed-rank test was performed for paired observations, to compare expression levels within groups, between 17 kDa and 28 kDa. For the pairwise comparison of 17 kDa and 28 kDa, a Bonferroni’s adjustment was made for the 2 hypothesis tests carried out within a cytokine. The 2 tests were carried out comparing 17 kDa and 28 kDa within the AIED group and within the control group, such that any given comparison required P < (0.05 / 2) = 0.025. Each experiment was repeated twice to confirm reproducibility.